5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one | 1044870-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one
• 英文别名: 5,7-dimethoxy-2-[4-methoxy-3-(morpholin-4-ylmethyl)phenyl]-3H-quinazolin-4-one
• CAS: 1044870-98-5
• 化学式: C₂₂H₂₅N₃O₅
• 分子量: 411.458
• InChiKey: AOJDYFWLCVYXPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  81.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-4,6-二甲氧基苯甲酰胺 、 4-甲氧基-3-(吗啉代甲基)苯甲醛 、 5,7-dimethoxy-2-(pyridin-2-yl)quinazolin-4(3H)-one 在 5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one 作用下， 以5,7-Dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one (65 mg, 28%) was isolated as a light yellow solid的产率得到5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one
  参考文献：
  名称：

  COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

  摘要：

  本公开涉及化合物，这些化合物有助于调节载脂蛋白A-I（ApoA-I）的表达，并且它们可以用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关的疾病，例如动脉粥样硬化。

  公开号：

  US20160106750A1
• 作为试剂：
  描述：

  2-氨基-4,6-二甲氧基苯甲酰胺 、 4-甲氧基-3-(吗啉代甲基)苯甲醛 、 5,7-dimethoxy-2-(pyridin-2-yl)quinazolin-4(3H)-one 在 5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one 作用下， 以5,7-Dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one (65 mg, 28%) was isolated as a light yellow solid的产率得到5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one
  参考文献：
  名称：

  Compounds for the prevention and treatment of cardiovascular diseases

  摘要：

  本公开涉及化合物，其可用于调节载脂蛋白A-I（ApoA-I）的表达，并且它们可用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如动脉粥样硬化。

  公开号：

  US09199990B2

文献信息

• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281398A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。
• NOVEL ANTI-INFLAMMATORY AGENTS
  申请人：Hansen Henrik C.

  公开号：US20120059002A1

  公开（公告）日：2012-03-08

  Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

  本发明涉及调节白细胞介素-6（IL-6）和/或血管细胞黏附分子-1（VCAM-1）的方法，以及治疗和/或预防心血管和炎症性疾病及相关疾病状态的方法，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化、牛皮癣和炎性肠病等自身免疫疾病，通过给予天然或合成的喹唑啉衍生物。该发明提供了新型合成喹唑啉化合物，以及包含这些化合物的药物组合物。
• Compositions and therapeutic methods for the treatment of complement-associated diseases
  申请人：Resverlogix Corp.

  公开号：US10111885B2

  公开（公告）日：2018-10-30

  The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

  本发明包括通过施用式 I 或式 II 的化合物，例如 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉-4(3H)-酮或其药学上可接受的盐，调节哺乳动物体内的补体级联，治疗和/或预防与补体途径相关的疾病和失调的方法。
• COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES
  申请人：Resverlogix Corp.

  公开号：US20160263126A1

  公开（公告）日：2016-09-15

  The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
• COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION
  申请人：LEBIODA Kenneth Eugene

  公开号：US20160346291A1

  公开（公告）日：2016-12-01

  The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of Formula I or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin.